Vista Current Coverage

All Pfizer Articles

Pfizer Beats Street Reporting Q4 & Full-Year 2017 Earnings

Pfizer (PFE) reported earnings on 1/30/2018 of $0.62/share firmly beating estimates of $0.583 per share. Pfizer’s abbreviated notes are as follows: Full-Year 2017 Revenues of $52.5 Billion, Comparable with Full-Year 2016 Operationally; Excluding Impact of February 2017 Divestiture of Hospira Infusion Systems (HIS), Revenues Increased...

Read “Running Strong” Vista Partners Weekly Market Update 1-27-18

Vista Partners has published  “Running Strong” Vista Partners Weekly Market Update 1-27-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that...

Vista Partners Quote of the Day Regarding Investing in “Spinoffs”

“The facts are overwhelming. Stocks of spinoff companies, and even shares of the parent companies that do the spinning off, significantly and consistently outperform the market averages.” – Joel Greenblatt Joel Greenblatt, born December 13, 1957,  is an American academic, hedge fund manager, investor, and writer....

How Do You Like The Sound of “24K”?

Vista Partners has published its Weekly Market Update for the week of December 2, 2017, titled “24K” Vista Partners Weekly Market Update 12-2-2017 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the...

Pfizer Granted Rights to Develop Novel Antifungal Medicine in Asia

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer Inc. (PFE) and Basilea Pharmaceutica Ltd. (BSLN.SW), an international biopharmaceutical company specializing in the research and development of anti-infective and oncological...